Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus? and metformin
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Early combination treatment strategy with vildagliptin (Galvus?) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2]
- The landmark VERIFY study is the first to investigate the long-term clinical benefits of this early combination strategy in type 2 diabetes (T2DM)[1]
- Novartis is committed to optimizing patient management of T2DM to achieve better glycemic control and favorable long-term clinical outcomes?
# # #
Novartis Global External Communications E-mail:?media.relations@novartis.comPeter Zuest Novartis Global External Communications +41 61 324 6383 (direct) +41 79 899 9812 (mobile) peter.zuest@novartis.com Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Meghan O?Donnell Global Head Communications and Patient Advocacy,? Cardio-Renal-Metabolism +41 61 324 9136 (direct) +41 79 797 9102 (mobile) meghan.odonnell@novartis.com Ruth Kuguru Head of Communications and Patient Advocacy, APMA Region +65 67226010 (direct) +65 9238 6791 (mobile) ruth.kuguru@novartis.com |